NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
QUEBEC CITY, Dec. 1, 2016 /CNW Telbec/ - Opsens Inc.
("Opsens" or the "Corporation") (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce that it has obtained a receipt for its
final short form prospectus (the "Prospectus") for its offering of up to 8,667,000 common shares of the Corporation (the "Shares")
at a price of $1.50 per Share for a maximum gross proceeds of approximately $13,000,500 (the "Offering"). The Offering will be conducted on a best effort basis through Paradigm Capital Inc.
("Paradigm"), acting as lead agent, and including RBC Capital Markets and M Partners Inc. (collectively with Paradigm, the
"Agents").
The Corporation has agreed to grant the Agents an option to cover over-allotments and for market stabilization purposes (the
"Over-Allotment Option"), which will allow the Agents to arrange for purchasers to acquire up to an additional 1,300,000 Shares
under the Offering. The Over-Allotment Option will be exercisable, in whole or in part, at any time up to 30 days after the closing
of the Offering.
The Corporation intends to use the net proceeds of the Offering to execute the commercialization and marketing strategy of its
Fractional Flow Reserve products ("FFR"), to fund research and product development and to fund its working capital.
The Offering is being made pursuant to the Prospectus which has been filed in each of the provinces of
Quebec, Ontario, Alberta and British Columbia. A copy of the Prospectus is available on SEDAR at www.sedar.com.
The Offering is expected to close on or about December 8, 2016 and is subject to certain customary
closing conditions. The TSX Venture Exchange ("TSXV") has conditionally approved the listing of the Shares to be issued pursuant to
the Prospectus.
This press release does not constitute an offer of securities for sale in the United States or to "U.S. persons"
("U.S. persons"), as such term is defined in Regulation S promulgated under the United States Securities Act of 1933, as amended
(the "U.S. Securities Act"). The securities being offered have not been, nor will be, registered under the U.S. Securities Act or
any state securities laws, and may not be offered or sold in the United States or to U.S. persons absent registration or
an applicable exemption from such registration requirements.
About Opsens Inc. (www.opsens.com
or www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure
guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved
in industrial activities. The Corporation develops, manufactures and installs innovative fibre optic sensing solutions for critical
applications, such as the monitoring of oil wells and other demanding industrial applications.
Except for historical information, this press release may contain "forward-looking statements" and "forward-looking
information" within the meaning of applicable securities laws that reflect Opsens' current expectation regarding future events,
including, without limitation the use of the net proceeds of the Offering and the timing and completion of the Offering.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that
may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or
achievements expressed or implied by the said forward-looking statements. Opsens expressly disclaims any intention to update or
revise any forward-looking statements and information whether as a result of new information, future events or otherwise, other
than as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE OPSENS INC.
